Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Templeton Global Equity Group’s CIO About ‘Overweight’ European and ‘Underweight’ Emerging Markets Stocks

In a recent interview with Bloomberg Television, Norman Boersma, the Chief Investment Office or Templeton Global Equity Group, which has $130 billion in assets under management,  provided his insights about developed and emerging market stocks.

Mr. Boersma considers that even though the Fed and the central bank of Japan are easing their policies, still the quantitative easing means that just less money being pumped into the system, as opposed to a reverse action and this move is still supportive for equities.

Currently Templeton has an “Underweight” rating for Emerging Markets stocks and “Overweight” for European stocks for the five-year horizon. Mr. Boersma stated that the rating for European stocks was set a couple of years back, when the European Central Bank President, Mario Draghi, said that they are going to support the peripheral countries.

“Stocks were unbelievably cheap back then. Nobody else really wanted to look at European stocks and if you had a five year view you would look basically out far enough and you would see the growth coming. […] Today a little less so, but still many good opportunities there.” Mr. Boersma pointed out.

However, this is not the case with the Emerging Markets, where people are just starting to really push the equities down, they are started to get interested, according to Mr. Boersma. In this way, Templeton has purchased some stocks in China and Russia, but there aren’t as many opportunities as have been a couple of years ago in Europe. However, Templeton is focused more on individual companies rather than on entire markets while picking their investments.

“We’ve been buying a little bit in China, a little bit in Russia, but we are certainly not finding the same magnitude of opportunities that we found a couple of years ago in Europe. […] In Russia there are really a couple of cash flow stories that are more in the material side of things and they benefit from a cheaper, weaker Rubble. […] In China there is a wide gambit of different types of companies,” Mr. Boersman said.

Watch the full interview below:

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!